The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period.A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-chagas-disease-management-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Chagas disease management market is segmented on the basis of treatment type, drug type, and end user
Based on treatment type, the Chagas disease management market segmented into the following:
Antiparasitic treatment
Symptomatic treatment
Based on drug type, the Chagas disease management market segmented into the following:
Benznidazole
Nifurtimox
Based on the distribution channel, the Chagas disease management market segmented into the following:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-chagas-disease-management-market/#ulp-c654SbFYO64MsOhu[/URL]
Chagas disease management market is still in the budding stage. Currently, very few players are actively involved in the development of new products for the Chagas disease treatment. Currently, there are only two drugs are available in the market for Chagas disease management namely, Benznidazole and Nifurtimox. Several products are in pipeline that may enter the market near future. Increase in research and developments for new products, acquisitions & mergers, collaborations and providing funds to various organizations for research and development activities might fuel the growth of Chagas disease management market. For instance, in March 2012, Dundee University partnered with GSK, Wellcome Trust for neglected tropical disease research. In June 2012, Japan’s Astellas Pharma signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to collaborate on drug discovery research for three neglected tropical diseases: leishmaniasis, Chagas disease, and sleeping sickness.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-chagas-disease-management-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in chagas disease management market are AstraZeneca (U.K), Bayer AG (Germany), Daiichi Sankyo Company Ltd (Japan), Eisai Co Ltd (Japan), GlaxoSmithKline Plc. (U.K), Grupo Praxis Pharmaceutical SA (Spain), KaloBios Pharmaceuticals, Inc. (U.S.), Kancera AB (Sweden), Novartis AG (Switzerland), Laboratorio Elea S.A.C.I.F. y A (Argentina), Oblita Therapeutics BVBA (Belgium), and Sanofi Aventis (France) to name a few.
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553"